

## **A New Gateway for Rheumatoid Arthritis: COXIBs with a Safety Cardiovascular Profile**

**Authors :** Malvina Hoxha, Valerie Capra, Carola Buccellati, Angelo Sala, Clara Cena, Roberta Fruttero, Massimo Bertinaria, G. Enrico Rovati

**Abstract :** Today COXIBs are used in the treatment of arthritis and many other painful conditions in selected patients with high gastrointestinal risk and low CV risk. Previously we found a new mechanism of action of a traditional NSAID (diclofenac) and a COXIB (lumiracoxib) that possess weak competitive antagonism at the TP receptor. We hypothesize that modifying the structure of a known specific inhibitor of cyclooxygenase-2 (COXIB), so that it becomes also a more potent thromboxane antagonist will preserve the anti-inflammatory and gastrointestinal safety typical of COXIBs and prevent the cardiovascular risk associated with long term therapy.

**Keywords :** cyclooxygenase, inflammation, lumiracoxib, thromboxane A2

**Conference Title :** ICPPS 2014 : International Conference on Pharmacology and Pharmaceutical Sciences

**Conference Location :** Venice, Italy

**Conference Dates :** April 14-15, 2014